Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
about
Clinical pharmacology in the adolescent oncology patient.Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.Optimizing drug development of anti-cancer drugs in children using modelling and simulation.Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.The adolescent and young adult with cancer: state of the art-- acute leukemias.Preventing and Managing Toxicities of High-Dose MethotrexateOptimal therapy for acute lymphoblastic leukemia in adolescents and young adults.Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation.Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma.Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.
P2860
Q30497854-A4E5EF33-69E1-47EF-B301-32B5A27305C0Q31103489-37924973-3598-4601-B8C1-743162460962Q33395001-9049F9A0-9FE2-4A2D-B55A-429677883190Q33952766-25A3F27D-CBE5-4504-B008-BD6B81572172Q34780653-2D5D6255-6CE0-4AED-A1B6-8F59D3DE5845Q34807224-1B9FA61B-3489-4280-8405-1661A42578B5Q36987975-24F29C4C-EE35-4717-9D2B-84E4F98C00BDQ37034349-3A2E31BA-0F52-43B8-983C-B03F3140D362Q37134753-526FB202-3597-4C86-A249-09833FB60A2AQ37496637-E94A47CF-24CF-48D1-A5FD-6BF107D665EEQ37883008-6A087504-568E-43E6-A39C-C39F07375EDDQ38003177-0AE343F0-A8BF-4C1E-8820-F0BE226B15EEQ38838930-0DEA9F6E-7663-4529-811D-329A1F40B126Q45068216-9F4F6753-2502-470D-A460-7894C964EBEDQ46459030-5D0FEF68-E437-4303-9FBA-69A0208A17D3Q47385414-8BCF1417-BE97-4E1B-BEE9-A6C0C0E9A303Q50856551-1F383751-143E-42FE-AE5C-E6633FDA336AQ55314183-0DBEB849-9DAD-46EA-BADA-49D852728F37
P2860
Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Population pharmacokinetics of ...... acute lymphoblastic leukaemia.
@en
Population pharmacokinetics of ...... acute lymphoblastic leukaemia.
@nl
type
label
Population pharmacokinetics of ...... acute lymphoblastic leukaemia.
@en
Population pharmacokinetics of ...... acute lymphoblastic leukaemia.
@nl
prefLabel
Population pharmacokinetics of ...... acute lymphoblastic leukaemia.
@en
Population pharmacokinetics of ...... acute lymphoblastic leukaemia.
@nl
P2093
P1476
Population pharmacokinetics of ...... acute lymphoblastic leukaemia.
@en
P2093
Antonio Torres
Dolores Aumente
Dolores Santos Buelga
John C Lukas
Maria José García
Pedro Gomez
P2860
P304
P356
10.2165/00003088-200645120-00007
P577
2006-01-01T00:00:00Z
P6179
1034635911